|
Ref
|
Population
|
Drug
|
Target
|
Antibody for PD-L1 IHC Assay
|
Definition of PD-L1 positivity
|
ORR (PD-L1+)
|
ORR (PD-L1-)
|
ORR All Patients
|
|---|
|
[6]
|
Post Platinum
|
Atezolizumab
|
PD-L1
|
Rabbit SP142 (Ventana)
|
IHC 2/3 ICa
|
43% (13/30)
|
11% (4/35)
|
26% (17/65)
|
|
[7]
|
Post Platinum
|
Atezolizumab
|
PD-L1
|
Rabbit SP142 (Ventana)
|
IHC 2/3 ICa
|
23% (26/113)
|
10% (36/349)
|
13% (63/462)
|
|
[3]
|
Post Platinum
|
Atezolizumab
|
PD-L1
|
Rabbit SP142 (Ventana)
|
IHC 2/3 ICa
|
26% (26/100)
|
9% (19/210)
|
15% (45/310)
|
|
[1]
|
Post Platinum
|
Pembrolizumab
|
PD-1
|
Mouse 22C3 (Dako)
|
CPS ≥ 10%b
|
22% (16/74)
|
22% (41/186)
|
21% (57/270)
|
|
[5]
|
Post Platinum
|
Nivolumab
|
PD-1
|
Rabbit 28–8 (Dako)
|
PD-L1 ≥ 5% (TC)
|
28% (23/81)
|
16% (29/184)
|
20% (52/265)
|
|
[7]
|
Post Platinum
|
Durvalumab
|
PD-L1
|
Rabbit SP263 (Ventana)
|
≥25% TC or ≥25% IC
|
28% (27/98)
|
5% (4/79)
|
18% (34/191)
|
|
[10]
|
Post Platinum
|
Avelumab
|
PD-L1
|
Rabbit 73–10 (Dako)
|
≥5% TC
|
54% (7/13)
|
4% (1/24)
|
21% (8/37)
|
|
[50]
|
Platinum Ineligible
|
Pembrolizumab
|
PD-1
|
Mouse 22C3 (Dako)
|
CPS ≥ 10%b
|
51% (41/80)
|
23% (42/185)
|
31% (83/265)
|
|
[12]
|
Platinum Ineligible
|
Atezolizumab
|
PD-L1
|
Rabbit SP142 (Ventana)
|
IHC 2/3 ICa
|
28% (9/32)
|
20% (18/87)
|
22% (27/119)
|
- TC tumor cells, Ref reference, IC percentage of PD-L1 positive immune cells in the tumor microenvironment, ORR overall response rate
- aIHC 2 is ≥5%, IHC 3 is ≥10%
- bCombined Positive Score = percentage of PD-L1 expressing tumor and infiltrating immune cells relative to the total number of tumor cells
